Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)

Balazs Halmos, Eng Huat Tan, Ross A. Soo, Jacques Cadranel, Min Ki Lee, Pascal Foucher, Te Chun Hsia, Maximilian Hochmair, Frank Griesinger, Toyoaki Hida, Edward Kim, Barbara Melosky, Angela Märten, Enric Carcereny

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Objectives: In the LUX-Lung clinical trials of afatinib in EGFR mutation-positive NSCLC, tolerability-guided dose adjustment reduced the incidence and severity of adverse events while maintaining efficacy. The RealGiDo study evaluated the impact of afatinib dose adjustment in a real-world setting. Materials and methods: This non-interventional, observational study used medical records of EGFR mutation-positive NSCLC patients treated with first-line afatinib. Primary outcomes were adverse drug reaction (ADR) incidence and severity, time to treatment failure (TTF), and time to progression (TTP), relative to LUX-Lung 3 (LL3). Results: 228 patients were enrolled from 13 countries. Baseline characteristics were in line with LL3 but with more Del19 patients (78.1% vs. 49.0%) and fewer Asian patients (43.9% vs. 72.2%); 11.8% had ECOG performance status 2–3. A total of 71 (31.1%) received a modified starting dose of ≤30 mg. Of patients who started with 40 mg, 67.1% underwent dose reductions, 86.5% of which were in the first 6 months. Dose reductions were mainly due to ADRs and were more common in female, East Asian, and low body-weight patients. There were no new safety signals and fewer ≥grade 3 ADRs (28.4% vs. 48.9%) and serious adverse events (5.2% vs. 14.0%) than in LL3. Median TTF and TTP were 18.7 and 20.8 months, respectively, and were not impacted by reduced starting dose or dose modification. Conclusion: Real-world data show that afatinib dose adjustments reduced the frequency and intensity of ADRs without compromising effectiveness, highlighting the benefit of tailoring afatinib dose to optimise treatment outcomes and supporting clinical decision-making. The study is registered at clinicaltrials.gov (NCT02751879).

Original languageEnglish (US)
Pages (from-to)103-111
Number of pages9
JournalLung Cancer
Volume127
DOIs
StatePublished - Jan 2019

    Fingerprint

Keywords

  • Afatinib
  • EGFR mutation-positive
  • Non-small-cell lung cancer
  • Real-world study

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Halmos, B., Tan, E. H., Soo, R. A., Cadranel, J., Lee, M. K., Foucher, P., Hsia, T. C., Hochmair, M., Griesinger, F., Hida, T., Kim, E., Melosky, B., Märten, A., & Carcereny, E. (2019). Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo). Lung Cancer, 127, 103-111. https://doi.org/10.1016/j.lungcan.2018.10.028